These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

363 related items for PubMed ID: 14555511

  • 1. Polymorphisms in BRCA1 and BRCA2 and risk of epithelial ovarian cancer.
    Wenham RM, Schildkraut JM, McLean K, Calingaert B, Bentley RC, Marks J, Berchuck A.
    Clin Cancer Res; 2003 Oct 01; 9(12):4396-403. PubMed ID: 14555511
    [Abstract] [Full Text] [Related]

  • 2. Common BRCA2 variants and modification of breast and ovarian cancer risk in BRCA1 mutation carriers.
    Hughes DJ, Ginolhac SM, Coupier I, Corbex M, Bressac-de-Paillerets B, Chompret A, Bignon YJ, Uhrhammer N, Lasset C, Giraud S, Hardouin A, Berthet P, Peyrat JP, Fournier J, Nogues C, Lidereau R, Muller D, Fricker JP, Longy M, Toulas C, Guimbaud R, Maugard C, Olschwang S, Yannoukakos D, Durocher F, Moisan AM, Simard J, Mazoyer S, Lynch HT, Szabo C, Lenoir GM, Goldgar DE, Stoppa-Lyonnet D, Sinilnikova OM.
    Cancer Epidemiol Biomarkers Prev; 2005 Jan 01; 14(1):265-7. PubMed ID: 15668505
    [Abstract] [Full Text] [Related]

  • 3. BRCA2 Arg372Hispolymorphism and epithelial ovarian cancer risk.
    Auranen A, Spurdle AB, Chen X, Lipscombe J, Purdie DM, Hopper JL, Green A, Healey CS, Redman K, Dunning AM, Pharoah PD, Easton DF, Ponder BA, Chenevix-Trench G, Novik KL.
    Int J Cancer; 2003 Jan 20; 103(3):427-30. PubMed ID: 12471628
    [Abstract] [Full Text] [Related]

  • 4. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.
    Pal T, Permuth-Wey J, Betts JA, Krischer JP, Fiorica J, Arango H, LaPolla J, Hoffman M, Martino MA, Wakeley K, Wilbanks G, Nicosia S, Cantor A, Sutphen R.
    Cancer; 2005 Dec 15; 104(12):2807-16. PubMed ID: 16284991
    [Abstract] [Full Text] [Related]

  • 5. Association between the BRCA2 N372H variant and male breast cancer risk: a population-based case-control study in Tuscany, Central Italy.
    Palli D, Falchetti M, Masala G, Lupi R, Sera F, Saieva C, D'Amico C, Ceroti M, Rizzolo P, Caligo MA, Zanna I, Ottini L.
    BMC Cancer; 2007 Sep 03; 7():170. PubMed ID: 17767707
    [Abstract] [Full Text] [Related]

  • 6. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
    Lose F, Duffy DL, Kay GF, Kedda MA, Spurdle AB, Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer, Australian Ovarian Cancer Study Management Group.
    J Natl Cancer Inst; 2008 Nov 05; 100(21):1519-29. PubMed ID: 18957670
    [Abstract] [Full Text] [Related]

  • 7. Missense polymorphisms in BRCA1 and BRCA2 and risk of breast and ovarian cancer.
    Dombernowsky SL, Weischer M, Freiberg JJ, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG.
    Cancer Epidemiol Biomarkers Prev; 2009 Aug 05; 18(8):2339-42. PubMed ID: 19661094
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The BRCA2 372 HH genotype is associated with risk of breast cancer in Australian women under age 60 years.
    Spurdle AB, Hopper JL, Chen X, Dite GS, Cui J, McCredie MR, Giles GG, Ellis-Steinborner S, Venter DJ, Newman B, Southey MC, Chenevix-Trench G.
    Cancer Epidemiol Biomarkers Prev; 2002 Apr 05; 11(4):413-6. PubMed ID: 11927503
    [Abstract] [Full Text] [Related]

  • 10. Progesterone receptor promoter +331A polymorphism is associated with a reduced risk of endometrioid and clear cell ovarian cancers.
    Berchuck A, Schildkraut JM, Wenham RM, Calingaert B, Ali S, Henriott A, Halabi S, Rodriguez GC, Gertig D, Purdie DM, Kelemen L, Spurdle AB, Marks J, Chenevix-Trench G.
    Cancer Epidemiol Biomarkers Prev; 2004 Dec 05; 13(12):2141-7. PubMed ID: 15598772
    [Abstract] [Full Text] [Related]

  • 11. Disease family history and modification of breast cancer risk in common BRCA2 variants.
    Seymour IJ, Casadei S, Zampiga V, Rosato S, Danesi R, Falcini F, Strada M, Morini N, Naldoni C, Paradiso A, Tommasi S, Schittulli F, Amadori D, Calistri D.
    Oncol Rep; 2008 Mar 05; 19(3):783-6. PubMed ID: 18288416
    [Abstract] [Full Text] [Related]

  • 12. Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutations.
    Wang-Gohrke S, Weikel W, Risch H, Vesprini D, Abrahamson J, Lerman C, Godwin A, Moslehi R, Olipade O, Brunet JS, Stickeler E, Kieback DG, Kreienberg R, Weber B, Narod SA, Runnebaum IB.
    Br J Cancer; 1999 Sep 05; 81(1):179-83. PubMed ID: 10487631
    [Abstract] [Full Text] [Related]

  • 13. Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group.
    Pharoah PD, Easton DF, Stockton DL, Gayther S, Ponder BA.
    Cancer Res; 1999 Feb 15; 59(4):868-71. PubMed ID: 10029077
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer.
    Chetrit A, Hirsh-Yechezkel G, Ben-David Y, Lubin F, Friedman E, Sadetzki S.
    J Clin Oncol; 2008 Jan 01; 26(1):20-5. PubMed ID: 18165636
    [Abstract] [Full Text] [Related]

  • 18. A single nucleotide polymorphism in the 5' untranslated region of RAD51 and risk of cancer among BRCA1/2 mutation carriers.
    Wang WW, Spurdle AB, Kolachana P, Bove B, Modan B, Ebbers SM, Suthers G, Tucker MA, Kaufman DJ, Doody MM, Tarone RE, Daly M, Levavi H, Pierce H, Chetrit A, Yechezkel GH, Chenevix-Trench G, Offit K, Godwin AK, Struewing JP.
    Cancer Epidemiol Biomarkers Prev; 2001 Sep 01; 10(9):955-60. PubMed ID: 11535547
    [Abstract] [Full Text] [Related]

  • 19. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.
    Milne RL, Osorio A, Cajal TR, Vega A, Llort G, de la Hoya M, Díez O, Alonso MC, Lazaro C, Blanco I, Sánchez-de-Abajo A, Caldés T, Blanco A, Graña B, Durán M, Velasco E, Chirivella I, Cardeñosa EE, Tejada MI, Beristain E, Miramar MD, Calvo MT, Martínez E, Guillén C, Salazar R, San Román C, Antoniou AC, Urioste M, Benítez J.
    Clin Cancer Res; 2008 May 01; 14(9):2861-9. PubMed ID: 18451254
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.